MedWatch

Fewer jobs in the biotech industry in the future

Even though Danish biotech still views itself as a growing industry, it will hardly be pharmaceutical biotech companies that will create the bulk of new jobs in the country in the future.

The dream of creating a new biotech adventure that would lead to thousands of new workplaces has been abandoned. In the future we will more likely see development-oriented companies with short life spans.

The industry and investors alike make that clear, not least after the streamlined biotech company Action Pharma last week announced the sale of its greatest asset – a promising candidate drug for kidney diseases – to the American pharmaceutical group Abbott for DKK 620 million.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier